These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26790544)

  • 1. Computational study on the drug resistance mechanism of HCV NS3 protease to BMS-605339.
    Wang H; Guo C; Chen BZ; Ji M
    Biotechnol Appl Biochem; 2017 Mar; 64(2):153-164. PubMed ID: 26790544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
    Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
    J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
    Xue W; Wang M; Jin X; Liu H; Yao X
    Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
    McPhee F; Friborg J; Levine S; Chen C; Falk P; Yu F; Hernandez D; Lee MS; Chaniewski S; Sheaffer AK; Pasquinelli C
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3670-81. PubMed ID: 22508297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
    Xue W; Pan D; Yang Y; Liu H; Yao X
    Antiviral Res; 2012 Jan; 93(1):126-37. PubMed ID: 22127068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.
    Cento V; Mirabelli C; Salpini R; Dimonte S; Artese A; Costa G; Mercurio F; Svicher V; Parrotta L; Bertoli A; Ciotti M; Di Paolo D; Sarrecchia C; Andreoni M; Alcaro S; Angelico M; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2012; 7(7):e39652. PubMed ID: 22792183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
    Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
    Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
    Ezat AA; Elshemey WM
    Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
    Wang H; Geng L; Chen BZ; Ji M
    Biochem Cell Biol; 2014 Oct; 92(5):357-69. PubMed ID: 25178998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
    Scola PM; Wang AX; Good AC; Sun LQ; Combrink KD; Campbell JA; Chen J; Tu Y; Sin N; Venables BL; Sit SY; Chen Y; Cocuzza A; Bilder DM; D'Andrea S; Zheng B; Hewawasam P; Ding M; Thuring J; Li J; Hernandez D; Yu F; Falk P; Zhai G; Sheaffer AK; Chen C; Lee MS; Barry D; Knipe JO; Li W; Han YH; Jenkins S; Gesenberg C; Gao Q; Sinz MW; Santone KS; Zvyaga T; Rajamani R; Klei HE; Colonno RJ; Grasela DM; Hughes E; Chien C; Adams S; Levesque PC; Li D; Zhu J; Meanwell NA; McPhee F
    J Med Chem; 2014 Mar; 57(5):1708-29. PubMed ID: 24555570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.
    Nagpal N; Goyal S; Wahi D; Jain R; Jamal S; Singh A; Rana P; Grover A
    Gene; 2015 Oct; 570(1):115-21. PubMed ID: 26055089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease.
    Iman K; Mirza MU; Sadia F; Froeyen M; Trant JF; Chaudhary SU
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.
    Scola PM; Sun LQ; Wang AX; Chen J; Sin N; Venables BL; Sit SY; Chen Y; Cocuzza A; Bilder DM; D'Andrea SV; Zheng B; Hewawasam P; Tu Y; Friborg J; Falk P; Hernandez D; Levine S; Chen C; Yu F; Sheaffer AK; Zhai G; Barry D; Knipe JO; Han YH; Schartman R; Donoso M; Mosure K; Sinz MW; Zvyaga T; Good AC; Rajamani R; Kish K; Tredup J; Klei HE; Gao Q; Mueller L; Colonno RJ; Grasela DM; Adams SP; Loy J; Levesque PC; Sun H; Shi H; Sun L; Warner W; Li D; Zhu J; Meanwell NA; McPhee F
    J Med Chem; 2014 Mar; 57(5):1730-52. PubMed ID: 24564672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
    Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
    J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
    Ehrenberg AE; Schmuck B; Anwar MI; Gustafsson SS; Stenberg G; Danielson UH
    J Enzyme Inhib Med Chem; 2014 Dec; 29(6):868-76. PubMed ID: 24517372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: a computational study.
    Pan D; Xue W; Zhang W; Liu H; Yao X
    Biochim Biophys Acta; 2012 Oct; 1820(10):1526-34. PubMed ID: 22698669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
    Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
    Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations.
    Guan Y; Sun H; Pan P; Li Y; Li D; Hou T
    Mol Biosyst; 2015 Sep; 11(9):2568-78. PubMed ID: 26219385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.